PMID- 32927498 OWN - NLM STAT- MEDLINE DCOM- 20201019 LR - 20231111 IS - 1469-493X (Electronic) IS - 1361-6137 (Linking) VI - 9 IP - 9 DP - 2020 Sep 14 TI - Systemic treatments for eczema: a network meta-analysis. PG - CD013206 LID - 10.1002/14651858.CD013206.pub2 [doi] LID - CD013206 AB - BACKGROUND: Eczema is a common and chronic, relapsing, inflammatory skin disorder. It seriously impacts quality of life and economic outcomes, especially for those with moderate to severe eczema. Various treatments allow sustained control of the disease; however, their relative benefit remains unclear due to the limited number of trials directly comparing treatments. OBJECTIVES: To assess the comparative efficacy and safety of different types of systemic immunosuppressive treatments for moderate to severe eczema using NMA and to generate rankings of available systemic immunosuppressive treatments for eczema according to their efficacy and safety. SEARCH METHODS: We searched the following databases up to August 2019: the Cochrane Skin Specialised Register, CENTRAL, MEDLINE, and Embase. SELECTION CRITERIA: All randomised controlled trials (RCTs) of systemic immunosuppressive agents for moderate to severe atopic eczema when compared against placebo or any other eligible eczema treatment. DATA COLLECTION AND ANALYSIS: We synthesised data using pair-wise analysis and NMA to compare treatments and rank them according to their effectiveness. Effectiveness was assessed primarily by determining the proportion of participants who achieved at least 75% improvement in the Eczema Area and Severity Index (EASI75) and improvement in the Patient-Oriented Eczema Measure (POEM). Safety was evaluated primarily by considering the proportion of participants with serious adverse events (SAEs) and infection. We deemed short-term follow-up as 16 weeks. We assessed the certainty of the body of evidence from the NMA for these primary outcomes using six domains of CiNEMA grading. MAIN RESULTS: We included a total of 74 studies, with 8177 randomised participants. Approximately 55% of participants were male, with average age of 32 years (range 2 to 84 years), although age and gender were unreported for 419 and 902 participants, respectively. Most of the included trials were placebo controlled (65%), 34% were head-to-head studies (15% assessed the effects of different doses of the same drug), and 1% were multi-armed studies with both an active comparator and a placebo. All trials included participants with moderate to severe eczema, but 62% of studies did not separate data by severity; 38% of studies assessed only severe eczema. The total duration of included trials ranged from 2 weeks to 60 months, whereas treatment duration varied from a single dose (CIM331, KPL-716) to 60 months (methotrexate (MTX)). Seventy studies were available for quantitative synthesis; this review assessed 29 immunosuppressive agents from three classes of interventions. These included (1) conventional treatments, with ciclosporin assessed most commonly; (2) small molecule treatments, including phosphodiesterase (PDE)-4 inhibitors, tyrosine kinase inhibitors, and Janus kinase (JAK) inhibitors; and (3) biological treatments, including anti-CD31 receptors, anti-interleukin (IL)-22, anti-IL-31, anti-IL-13, anti-IL-12/23p40, anti-OX40, anti-TSLP, anti-CRTH2, and anti-immunoglobulin E (IgE) monoclonal antibodies, but most commonly dupilumab. Most trials (73) assessed outcomes at a short-term duration ranging from 2 to 16 weeks, whereas 33 trials assessed long-term outcomes, with duration ranging from 5 to 60 months. All participants were from a hospital setting. Fifty-two studies declared a source of funding, and of these, pharmaceutical companies funded 88%. We rated 37 studies as high risk; 21, unclear risk, and 16, low risk of bias, with studies most commonly at high risk of attrition bias. Network meta-analysis suggests that dupilumab ranks first for effectiveness when compared with other biological treatments. Dupilumab is more effective than placebo in achieving EASI75 (risk ratio (RR) 3.04, 95% confidence interval (CI) 2.51 to 3.69) and improvement in POEM score (mean difference 7.30, 95% CI 6.61 to 8.00) at short-term follow-up (high-certainty evidence). Very low-certainty evidence means we are uncertain of the effects of dupilumab when compared with placebo, in terms of the proportion of participants who achieve EASI75 (RR 2.59, 95% CI 1.87 to 3.60) at longer-term follow-up. Low-certainty evidence indicates that tralokinumab may be more effective than placebo in achieving short-term EASI75 (RR 2.54, 95% CI 1.21 to 5.34), but there was no evidence for tralokinumab to allow us to assess short-term follow-up of POEM or long-term follow-up of EASI75. We are uncertain of the effect of ustekinumab compared with placebo in achieving EASI75 (long-term follow-up: RR 1.17, 95% CI 0.40 to 3.45; short-term follow-up: RR 0.91, 95% CI 0.28 to 2.97; both very low certainty). We found no evidence on ustekinumab for the POEM outcome. We are uncertain whether other immunosuppressive agents that targeted our key outcomes influence the achievement of short-term EASI75 compared with placebo due to low- or very low-certainty evidence. Dupilumab and ustekinumab were the only immunosuppressive agents evaluated for longer-term EASI75. Dupilumab was the only agent evaluated for improvement in POEM during short-term follow-up. Low- to moderate-certainty evidence indicates a lower proportion of participants with SAEs after treatment with QAW039 and dupilumab compared to placebo during short-term follow-up, but low- to very low-certainty evidence suggests no difference in SAEs during short-term follow-up of other immunosuppressive agents compared to placebo. Evidence for effects of immunosuppressive agents on risk of any infection during short-term follow-up and SAEs during long-term follow-up compared with placebo was of low or very low certainty but did not indicate a difference. We did not identify differences in other adverse events (AEs), but dupilumab is associated with specific AEs, including eye inflammation and eosinophilia. AUTHORS' CONCLUSIONS: Our findings indicate that dupilumab is the most effective biological treatment for eczema. Compared to placebo, dupilumab reduces eczema signs and symptoms in the short term for people with moderate to severe atopic eczema. Short-term safety outcomes from clinical trials did not reveal new safety concerns with dupilumab. Overall, evidence for the efficacy of most other immunosuppressive treatments for moderate to severe atopic eczema is of low or very low certainty. Given the lack of data comparing conventional with newer biological treatments for the primary outcomes, there remains high uncertainty for ranking the efficacy and safety of conventional treatments such as ciclosporin and biological treatments such as dupilumab. Most studies were placebo-controlled and assessed only short-term efficacy of immunosuppressive agents. Further adequately powered head-to-head RCTs should evaluate comparative long-term efficacy and safety of available treatments for moderate to severe eczema. CI - Copyright (c) 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. FAU - Sawangjit, Ratree AU - Sawangjit R AD - Department of Clinical Pharmacy, Faculty of Pharmacy, Mahasarakham University, Mahasarakham, Thailand. FAU - Dilokthornsakul, Piyameth AU - Dilokthornsakul P AD - Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Naresuan University, Phitsanulok, Thailand. FAU - Lloyd-Lavery, Antonia AU - Lloyd-Lavery A AD - Department of Dermatology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK. FAU - Lai, Nai Ming AU - Lai NM AD - School of Medicine, Taylor's University, Subang Jaya, Malaysia. FAU - Dellavalle, Robert AU - Dellavalle R AD - University of Colorado School of Medicine, Denver, Colorado, USA. FAU - Chaiyakunapruk, Nathorn AU - Chaiyakunapruk N AD - Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, Utah, USA. LA - eng PT - Journal Article PT - Meta-Analysis PT - Research Support, Non-U.S. Gov't PT - Systematic Review DEP - 20200914 PL - England TA - Cochrane Database Syst Rev JT - The Cochrane database of systematic reviews JID - 100909747 RN - 0 (Antibodies, Monoclonal) RN - 0 (Antibodies, Monoclonal, Humanized) RN - 0 (Dermatologic Agents) RN - 0 (Immunosuppressive Agents) RN - 0 (Placebos) RN - 420K487FSG (dupilumab) RN - FU77B4U5Z0 (Ustekinumab) RN - GK1LYB375A (tralokinumab) SB - IM UOF - doi: 10.1002/14651858.CD013206 MH - Adolescent MH - Adult MH - Aged MH - Aged, 80 and over MH - Antibodies, Monoclonal/therapeutic use MH - Antibodies, Monoclonal, Humanized/therapeutic use MH - Child MH - Child, Preschool MH - Dermatologic Agents/*therapeutic use MH - Eczema/*drug therapy MH - Female MH - Humans MH - Immunosuppressive Agents/*therapeutic use MH - Male MH - Middle Aged MH - *Network Meta-Analysis MH - Placebos/therapeutic use MH - Randomized Controlled Trials as Topic MH - Treatment Outcome MH - Ustekinumab/therapeutic use MH - Young Adult PMC - PMC8128359 COIS- Ratree Sawangjit: none declared.
Piyameth Dilokthornsakul: none declared.
Antonia Lloyd-Lavery: none declared.
Nai Ming Lai: none declared.
Robert Dellavalle: serves as Cochrane Skin Joint Co-ordinating Editor (starting 15 January 2018). He receives an editorial stipend for serving as Social Media Editor and reimbursement for annual editorial board meeting expenses from the Journal of the American Academy of Dermatology, an editorial stipend from the Journal of Investigative Dermatology for serving as Podcast Editor, and reimbursement for travel to the Dermatology Foundation annual grant review meeting, where he serves as a grant reviewer. He receives royalties from UpToDate, for which he serves as a dermatology section editor. He has served as the principal investigator on independent grants from Pfizer Pharmaceuticals to the University of Colorado, which develops patient decision aids for dermatological diseases.
Nathorn Chaiyakunapruk: none declared. EDAT- 2020/09/15 06:00 MHDA- 2020/10/21 06:00 PMCR- 2021/09/14 CRDT- 2020/09/14 20:24 PHST- 2020/09/14 20:24 [entrez] PHST- 2020/09/15 06:00 [pubmed] PHST- 2020/10/21 06:00 [medline] PHST- 2021/09/14 00:00 [pmc-release] AID - CD013206.pub2 [pii] AID - 10.1002/14651858.CD013206.pub2 [doi] PST - epublish SO - Cochrane Database Syst Rev. 2020 Sep 14;9(9):CD013206. doi: 10.1002/14651858.CD013206.pub2.